2 weeks Ago By ABMN Staff
StockNews.com initiated coverage on shares of Bio-Path ( NASDAQ:BPTH – Get Free Report ) in a research note issued on Sunday. The firm set a “sell” rating on the stock.
Bio-Path Stock Up 2.6 % Shares of BPTH stock opened at $0.82 on Friday.
The firm’s 50 day moving average price is $0.97 and its two-hundred day moving average price is $1.51.
Bio-Path has a 52-week low of $0.61 and a 52-week high of $12.37.
Hedge Funds Weigh In On Bio-Path An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new stake in Bio-Path Holdings, Inc. ( NASDAQ:BPTH – Free Report ) during the second quarter, according to its most recent filing with the SEC.
The firm purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period.
Institutional investors own 5.74% of the company’s stock. About Bio-Path Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Read More Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter .
.
